Study: AD, OCD Linked
People with atopic dermatitis (AD) may be up to three times as likely to develop obsessive-compulsive disorder (OCD), according to a research letter published in the December 2023 issue of the Archives of Dematological Research. When Yale School of Medicine researchers examined data from more than 214,000 participants in the All of Us Research Program, they found that people […]
Is an Acne Vaccine on the Horizon?
A new vaccine targeting a variant of hyaluronidase may reduce acne-related inflammation, according to research in mice in Nature Communications. Researchers identified two variants of hyaluronidase, an enzyme produced by Cutibacterium acnes (C. acnes). One variant, called HylA, is strictly made by C. acnes that are associated with acne. The other variant (HylB) is made by C. acnes […]
JAK of All Trades, Master of Some? New Research Highlights Tissue-Specific Roles of JAK Signaling
Janus kinase (JAK) inhibitors are revolutionizing the way certain inflammatory diseases such as atopic dermatitis (AD) are being treated, but a more nuanced approach may be needed in modulating JAK activity for conditions like asthma. This is the main takeaway message from a new study in the December 21, 2023, issue of Cell. For the […]
Boston Dermatologist Wins Skin Ageing & Challenges Best Scientific Award 2023 for Research on Skin Biology, Aging
Professor Vladimir A. Botchkarev, MD, PhD, a distinguished Professor of Dermatology and Co-Director at the Boston University Center for Aging Research, has received the Skin Ageing & Challenges Best Scientific Award for 2023. The award, which was presented at The Skin Ageing & Challenges 2023 Conference in Lisbon, is for his paper titled “Skin Aging in Long-Lived Naked […]
TDD Alopecia Pipeline Watch: Enrollment Complete for Equillium’s Phase 2 Study of EQ101 in AA
Equillium, Inc. has completed enrollment of the EQ101 Phase 2 study in alopecia areata, the Company reports. EQ101 is a first-in-class, selective, tri-specific inhibitor of interleukin (IL)-2, IL-9 and IL-15. The study enrolled 36 patients, of which 13, or 36%, had severe alopecia areata. The study remains ongoing, but EQ101 has been well tolerated over the […]
Evolus on the Move: Company Joins Forces With Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
Evolus, Inc. has entered into a definitive agreement with Symatese to be the exclusive distributor in the United Kingdom (U.K.) and Europe of four unique dermal fillers in late-stage development with anticipated regulatory clearances in the second half of 2024 and commercialization under the brand name Estyme (pronounced “esteem”) fillers in 2025. This marks the second […]
Study: The Number of New Dermatology Drugs Approved by the FDA Is on the Rise
The number of new dermatologic drug approvals by the U.S. Food and Drug Administration (FDA) increased between 2012 and 2022 compared with prior decades, according to a research letter in JAMA Dermatology. Nearly half of these drugs were considered first in class or first in indication, and several were deemed clinically useful or to have high […]
TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology
Sudo Biosciences Raises $116M Series B Financing to Advance TYK2 Therapeutics Programs Into the Clinic Sudo Biosciences raised $116 million Series B financing to advance two investigational TYK2 candidates into the clinic in 2024. Sudo is developing a potential first-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases. In addition, Sudo’s CNS program is […]
Long-term Use of Steroid Creams Linked to Osteoporosis, Fractures
Higher doses of topical corticosteroids may increase risk of the brittle bone disease osteoporosis and associated fractures, according to research in the Journal of the European Academy of Dermatology and Venereology. Investigators selected 129,682 osteoporosis cases and 34,999 major osteoporotic fracture (MOF) cases and matched them with 518,728 and 139,996 controls (without osteoporosis or MOF) by […]
FDA Approves FILSUVEZ Topical Gel for Junctional and Dystrophic EB
The U.S. Food and Drug Administration (FDA) approved FILSUVEZ (birch triterpenes) topical gel for the treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB). Chiesi Global Rare Diseases’ FILSUVEZ is the first approved treatment for wounds associated with JEB, a rare, moderate-to-severe form of […]